Physician profile

Thomas J Burke

Dermatology · Newark, DE

NPI 1881698389

$20,538.55

in general payments reported to CMS, 2019-2025

42 companies · $3,848 in 2025

The $3,848 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).

See the full distribution for Dermatology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$10,240.15
Education$79.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $3,266.18 2019-2025 Skyrizi, Rinvoq
Janssen Biotech, INC. $2,444.58 2019-2025 Tremfya, Simponi Aria, Stelara
Novartis Pharmaceuticals Corporation $2,225.60 2019-2025
Ucb, INC. $1,480.10 2019-2025 Bimzelx, Cimzia
Amgen INC. $1,224.22 2019-2025 Otezla, Otezla
Lilly USA, LLC $1,065.02 2019-2025 Taltz, Olumiant, Ebglyss
E.R. Squibb & Sons, L.L.C. $1,019.05 2022-2025 Sotyktu
Regeneron Healthcare Solutions, INC. $999.13 2019-2025 Dupixent, Libtayo
Leo Pharma INC. $883.52 2021-2025 Adbry, Anzupgo
Pfizer INC. $820.00 2019-2025
Sun Pharmaceutical Industries INC. $718.73 2019-2025 Ilumya, Odomzo, Blu-U
Incyte Corporation $645.36 2021-2025 Opzelura
Genentech USA, INC. $507.15 2019-2025 Xolair, Erivedge
Galderma Laboratories, L.P. $431.86 2020-2025 Nemluvio, Aklief, Oracea
Genzyme Corporation $427.13 2019-2025
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Merz North America, INC. $327.97 2019-2025
Ortho Dermatologics, A Division of Bausch Health US, LLC $249.77 2019-2025 Siliq, Targretin
Arcutis Biotherapeutics, INC. $227.81 2023-2025 Zoryve
Organon LLC $176.26 2025 Vtama
Fresenius Kabi USA, LLC $170.63 2023-2024 Idacio
Organogenesis INC. $153.69 2020-2021
Prugen, INC. Pharmaceuticals $132.65 2019-2020
Celgene Corporation $129.73 2019
Biofrontera INC. $98.43 2019-2024 Xepi, Bf-Rhodoled, Ameluz
Almirall LLC $89.54 2024-2025 Klisyri, Seysara
Dermavant Sciences, INC. $77.80 2023 Vtama
Epi Health, LLC $70.73 2020-2021
Strata Skin Sciences, INC. $70.66 2022-2024 Xtrac
Mallinckrodt Hospital Products INC. $68.15 2025 Acthar
Vyne Pharmaceuticals INC. $64.53 2020-2021
Journey Medical Corporation $53.51 2019-2023
Taro Pharmaceuticals USA, INC. $30.81 2019
Mission Pharmacal Company $29.95 2019-2020
Kerecis Limited $29.35 2024 Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose
Kyowa Kirin, INC. $20.98 2022
Aclaris Therapeutics, INC. $20.22 2019
Boehringer Ingelheim Pharmaceuticals, INC. $18.82 2023 Spevigo
G Medical Diagnostic Services, INC. $14.71 2022
Conmed Corporation $14.36 2023 Visiclear
Sandoz INC. $14.16 2024 Hyrimoz
Dusa Pharmaceuticals, INC. $13.88 2019
Blueprint Medicines Corporation $11.82 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas J Burke

$20,538.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $3,848 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/357436/thomas-j-burke

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.